Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa

Gastroenterology

Volumn 137, Issue 6, 2009, Pages 2002-2009

  Buster, Erik H C J ^a   Hansen, Bettina E ^a   Lau, George K K ^b   Piratvisuth, Teerha ^c   Zeuzem, Stefan ^d   Steyerberg, Ewout W ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c Songklanakarin Hospital   (Thailand)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENDER; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 70649104668     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.08.061     Document Type: Article

References (47)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
2. Lok A.S., Lai C.L., Wu P.C., et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92 (1987) 1839-1843
3. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
4. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
5. van Zonneveld M., Honkoop P., Hansen B.E., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
6. Buster E.H., Flink H.J., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology 135 (2008) 459-467
7. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
8. Lin S.M., Sheen I.S., Chien R.N., et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
9. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
10. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
11. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
12. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
13. Carreno V., Castillo I., Molina J., et al. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 15 (1992) 102-106
14. Fattovich G., Giustina G., Realdi G., et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 26 (1997) 1338-1342
15. Korenman J., Baker B., Waggoner J., et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114 (1991) 629-634
16. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 5 (1998) 389-397
17. Lok A.S., Chung H.T., Liu V.W., et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105 (1993) 1833-1838
18. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
19. van Zonneveld M., Flink H.J., Verhey E., et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 21 (2005) 1163-1171
20. van Nunen A.B., Hansen B.E., Suh D.J., et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52 (2003) 420-424
21. Leung N.W., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
22. Chang T.T., Lai C.L., Chien R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 (2004) 1276-1282
23. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
24. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
25. Cooksley G., Lau G.K.K., Liaw Y.F., et al. Effects of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys®) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol 42 (2005) S30
26. Bonino F., Lau G.K.K., Marcellin P., et al. The first detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: data from a multicenter, randomized, partially double-blind study of peginterferon-alfa-2a (4-KD) (Pegasys®) alone or in combination with lamivudine vs lamivudine alone. Hepatology 40 (2004) A1142
27. European Association for the study of the liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50 (2009) 227-242
28. Pas S.D., Fries E., De Man R.A., et al. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 38 (2000) 2897-2901
29. Harrell Jr. F.E. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis (2001), Springer-Verlag, New York, NY
30. Steyerberg E.W., Eijkemans M.J., Harrell Jr. F.E., et al. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19 (2000) 1059-1079
31. Steyerberg E.W., Harrell Jr. F.E., Borsboom G.J., et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54 (2001) 774-781
32. Harrell F.E. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis (2006), Springer-Verlag, LLC, New York
33. de Franchis R., Hadengue A., Lau G., et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002, Geneva, Switzerland. Consensus statement (long version). J Hepatol 39 (2003) S3-S25
34. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2 (2008) 263-283
35. Chien R.N., Yeh C.T., Tsai S.L., et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 (2003) 1267-1273
36. Ryu S.H., Chung Y.H., Choi M.H., et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 39 (2003) 614-619
37. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
38. Poynard T., Hou J.L., Chutaputti A., et al. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine. J Hepatol 48 (2008) S263-S264
39. Zoulim F., and Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 48 Suppl 1 (2008) S2-S19
40. Craxi A., Di Bona D., and Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 39 Suppl 1 (2003) S99-S105
41. Fried M.W., Piratvisuth T., Lau G.K., et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47 (2008) 428-434
42. Buster E.H., Hansen B.E., Zeuzem S., et al. Predicting sustained HBeAg loss after treatment with peginterferon alpha-2b: development and validation of a practical model. Hepatology 46 (2007) 684A-685A
43. Grandjacques C., Pradat P., Stuyver L., et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 33 (2000) 430-439
44. Lin S.M., Yu M.L., Lee C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
45. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
46. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
47. Marcellin P., Piratvisuth T., Brunetto M.R., et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) with or without lamivudine: results of 4-year follow-up. J Hepatol 48 (2008) S46